A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

Conditions:   Solid Tumor;   Breast Cancer;   Cancer of Head and Neck
Interventions:   Drug: RO6874281;   Drug: Trastuzumab;   Drug: Cetuximab
Sponsor:   Hoffmann-La Roche
Recruiting

http://ift.tt/2Fnoygi